Last reviewed · How we verify
BIIB022 With Paclitaxel and Carboplatin
BIIB022 With Paclitaxel and Carboplatin is a Small molecule drug developed by Biogen. It is currently in Phase 1 development. Also known as: Taxol, Paraplatin, BIIB022, Taxane.
At a glance
| Generic name | BIIB022 With Paclitaxel and Carboplatin |
|---|---|
| Also known as | Taxol, Paraplatin, BIIB022, Taxane, Anti-IGF-1R |
| Sponsor | Biogen |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- BIIB022 With Paclitaxel and Carboplatin CI brief — competitive landscape report
- BIIB022 With Paclitaxel and Carboplatin updates RSS · CI watch RSS
- Biogen portfolio CI
Frequently asked questions about BIIB022 With Paclitaxel and Carboplatin
What is BIIB022 With Paclitaxel and Carboplatin?
BIIB022 With Paclitaxel and Carboplatin is a Small molecule drug developed by Biogen.
Who makes BIIB022 With Paclitaxel and Carboplatin?
BIIB022 With Paclitaxel and Carboplatin is developed by Biogen (see full Biogen pipeline at /company/biogen).
Is BIIB022 With Paclitaxel and Carboplatin also known as anything else?
BIIB022 With Paclitaxel and Carboplatin is also known as Taxol, Paraplatin, BIIB022, Taxane, Anti-IGF-1R.
What development phase is BIIB022 With Paclitaxel and Carboplatin in?
BIIB022 With Paclitaxel and Carboplatin is in Phase 1.
Related
- Manufacturer: Biogen — full pipeline
- Also known as: Taxol, Paraplatin, BIIB022, Taxane, Anti-IGF-1R
- Compare: BIIB022 With Paclitaxel and Carboplatin vs similar drugs
- Pricing: BIIB022 With Paclitaxel and Carboplatin cost, discount & access